Skye Bioscience Statistics
Total Valuation
Skye Bioscience has a market cap or net worth of $17.62 million. The enterprise value is $7.74 million.
| Market Cap | 17.62M |
| Enterprise Value | 7.74M |
Important Dates
The next estimated earnings date is Monday, August 17, 2026, after market close.
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Skye Bioscience has 35.14 million shares outstanding. The number of shares has increased by 0.69% in one year.
| Current Share Class | 35.14M |
| Shares Outstanding | 35.14M |
| Shares Change (YoY) | +0.69% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 4.96% |
| Owned by Institutions (%) | 11.73% |
| Float | 21.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.95
| Current Ratio | 0.95 |
| Quick Ratio | 0.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8,847.90 |
Financial Efficiency
Return on equity (ROE) is -233.87% and return on invested capital (ROIC) is -139.07%.
| Return on Equity (ROE) | -233.87% |
| Return on Assets (ROA) | -96.22% |
| Return on Invested Capital (ROIC) | -139.07% |
| Return on Capital Employed (ROCE) | 9,781.83% |
| Weighted Average Cost of Capital (WACC) | 20.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$25.25M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Skye Bioscience has paid $3,400 in taxes.
| Income Tax | 3,400 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.03% in the last 52 weeks. The beta is 2.99, so Skye Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 2.99 |
| 52-Week Price Change | -84.03% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.87 |
| Relative Strength Index (RSI) | 33.89 |
| Average Volume (20 Days) | 191,966 |
Short Selling Information
The latest short interest is 1.32 million, so 3.75% of the outstanding shares have been sold short.
| Short Interest | 1.32M |
| Short Previous Month | 1.05M |
| Short % of Shares Out | 3.75% |
| Short % of Float | 6.07% |
| Short Ratio (days to cover) | 11.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.65M |
| Pretax Income | -50.49M |
| Net Income | -50.49M |
| EBITDA | -47.96M |
| EBIT | -48.65M |
| Earnings Per Share (EPS) | -$1.28 |
Balance Sheet
The company has $10.06 million in cash and $178,746 in debt, with a net cash position of $9.89 million or $0.28 per share.
| Cash & Cash Equivalents | 10.06M |
| Total Debt | 178,746 |
| Net Cash | 9.89M |
| Net Cash Per Share | $0.28 |
| Equity (Book Value) | -497,307 |
| Book Value Per Share | -0.01 |
| Working Capital | -572,215 |
Cash Flow
| Operating Cash Flow | -42.43M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 718,859 |
| Net Borrowing | -71,525 |
| Free Cash Flow | -42.43M |
| FCF Per Share | -$1.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Skye Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.69% |
| Shareholder Yield | -0.69% |
| Earnings Yield | -286.49% |
| FCF Yield | -240.77% |
Analyst Forecast
The average price target for Skye Bioscience is $7.33, which is 1,361.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.33 |
| Price Target Difference | 1,361.62% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:250.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:250 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |